{"id":8790,"date":"2020-03-31T17:40:39","date_gmt":"2020-03-31T12:10:39","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=8790"},"modified":"2021-07-24T12:57:51","modified_gmt":"2021-07-24T07:27:51","slug":"recent-pharma-happenings-for-j-and-j-abbott-gigagen-cobra-biologics","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-j-and-j-abbott-gigagen-cobra-biologics","title":{"rendered":"J&#038;J&#8217;s COVID-19 Vaccine; GigaGen COVID-19 therapy; FDA approved Abbott&#8217;s POC test; Cobra Bio raises $ 3.3 M"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f57413917b9\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f57413917b9\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-j-and-j-abbott-gigagen-cobra-biologics\/#Johnson_Johnson_is_fast-forwarding_its_vaccine_development_program_for_COVID-19\" >Johnson &amp; Johnson is fast-forwarding its vaccine development program for COVID-19.&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-j-and-j-abbott-gigagen-cobra-biologics\/#GigaGen_is_developing_a_recombinant_polyclonal_antibody_therapy_rCIG_to_treat_COVID-19\" >GigaGen is developing a recombinant polyclonal antibody therapy (rCIG) to treat COVID-19.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-j-and-j-abbott-gigagen-cobra-biologics\/#The_US_FDA_has_approved_Abbotts_new_point-of-care_test_for_the_novel_coronavirus_under_EUA\" >The US FDA has approved Abbott&#8217;s new point-of-care test for the novel coronavirus under EUA.&nbsp;&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-j-and-j-abbott-gigagen-cobra-biologics\/#Cobra_Biologics_secures_USD_33_Million_to_develop_a_DNA_vaccine_against_COVID-19\" >Cobra Biologics secures USD 3.3 Million to develop a DNA vaccine against COVID-19.&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Johnson_Johnson_is_fast-forwarding_its_vaccine_development_program_for_COVID-19\"><\/span><strong>Johnson &amp; Johnson is fast-forwarding its vaccine development program for COVID-19.&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The healthcare company has selected a lead vaccine candidate and is planning to begin human trials in September, with first batches available under potential emergency use authorization in the first part of 2021.<\/p>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus\/\">COVID-19<\/a> vaccine program is using Janssen&#8217;s AdVac and PER.C6 technologies. These platforms can rapidly develop new vaccine candidates and accelerate the production of the optimal vaccine candidate.&nbsp;<\/p>\n\n\n\n<p>The company has used the same platform for the manufacturing of its Ebola vaccine and construct its Zika, RSV, and HIV vaccine candidates who are in Phase II and Phase III.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"GigaGen_is_developing_a_recombinant_polyclonal_antibody_therapy_rCIG_to_treat_COVID-19\"><\/span><strong>GigaGen is developing a recombinant polyclonal antibody therapy (rCIG) to treat COVID-19.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The company is working towards filing an IND and is planning to start clinical trials for the treatments for severely ill coronavirus patients and individuals at high risk of contracting the disease, including healthcare professionals.<\/p>\n\n\n\n<p>GigaGen&#8217;s rCIG technology has the potential to deliver high concentrations of a comprehensive repertory of antibodies that combat the <a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus-2019-ncov-is-now-covid-19\/\">COVID-19<\/a> virus by capturing tens of thousands of antibodies to COVID-19 from the serum of scores of patients who have recovered from this virus. After replicated and developed into a vaccine, the antibodies should be able to coat the virus halting the viral particle replication.&nbsp;<\/p>\n\n\n\n<p>The company has been developing recombinant immunoglobulin technologies for therapeutics for several years. The technology has been validated in mouse models, with recombinant polyclonal antibodies targeting Zika virus, Haemophilus influenza B, Influenza A, and Hepatitis B.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_US_FDA_has_approved_Abbotts_new_point-of-care_test_for_the_novel_coronavirus_under_EUA\"><\/span><strong>The US FDA has approved Abbott&#8217;s new point-of-care test for the novel coronavirus under EUA.&nbsp;&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Abbott&#8217;s new assay can deliver the results \u2013 if confirmed positive for the virus in a as little as five minutes and in thirteen minutes if confirmed negative.&nbsp;<\/p>\n\n\n\n<p>The test uses the company&#8217;s ID NOW platform, which is already a widely available molecular point-of-care testing platform in the United States.<\/p>\n\n\n\n<p>The company is joining numerous other pharma and biotech players who have their diagnostic test approved under emergency use for <a href=\"https:\/\/www.delveinsight.com\/blog\/questions-and-answers-on-coronavirus-covid-19\/\">COVID-19<\/a> such including PerkinElmer, Roche, LabCorp, Quest Diagnostics, Truvian Sciences and others.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Cobra_Biologics_secures_USD_33_Million_to_develop_a_DNA_vaccine_against_COVID-19\"><\/span><strong>Cobra Biologics secures USD 3.3 Million to develop a DNA vaccine against COVID-19.&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>UK-based company and Sweden-based medical university &#8211; the Karolinska Institute have secured millions in emergency funding from Horizon 2020 to actively develop a vaccine to prevent <a href=\"https:\/\/www.delveinsight.com\/blog\/realm-of-pandemics\/\">COVID-19<\/a> as part of the OPENCORONA consortium.&nbsp;<\/p>\n\n\n\n<p>The main goal of the companies is to support research and development and lead the development to Phase I clinical trial testing of a DNA vaccine against COVID-19.<\/p>\n\n\n\n<p>OPENCORONA is a collaboration aimed at combating COVID-19, the disease which has managed to infect over 730,000 individuals. Partners in the consortium also include Karolinska University Hospital, Public Health Authority (FoHM), IGEA, Adlego AB and Giessen University.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Johnson &amp; Johnson is fast-forwarding its vaccine development program for COVID-19.&nbsp; The healthcare company has selected a lead vaccine candidate and is planning to begin human trials in September, with first batches available under potential emergency use authorization in the first part of 2021. The COVID-19 vaccine program is using Janssen&#8217;s AdVac and PER.C6 technologies. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8798,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2405,18181,10830,18179,18180,2734,17452,420,18182,639,18183,5789,524,17825],"industry":[17225],"therapeutic_areas":[17231,17243],"class_list":["post-8790","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-abbott","tag-cobra-biologics","tag-covid-19","tag-ebola-vaccine","tag-gigagen","tag-johnson-and-johnson","tag-labcorp","tag-news","tag-perkinelmer","tag-pharma-news","tag-quest-diagnostics","tag-recent-pharma-news","tag-roche","tag-truvian-sciences","industry-pharmaceutical","therapeutic_areas-infectious-diseases","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>COVID-19 Vaccine Update; Abbott&#039;s POC test; Cobra Bio raises $ 3.3M<\/title>\n<meta name=\"description\" content=\"The US FDA has approved Abbott&#039;s new point-of-care test for the novel coronavirus (COVID-19) under EUA. Abbott&#039;s new assay can deliver the results in five..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-j-and-j-abbott-gigagen-cobra-biologics\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"COVID-19 Vaccine Update; Abbott&#039;s POC test; Cobra Bio raises $ 3.3M\" \/>\n<meta property=\"og:description\" content=\"The US FDA has approved Abbott&#039;s new point-of-care test for the novel coronavirus (COVID-19) under EUA. Abbott&#039;s new assay can deliver the results in five..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-j-and-j-abbott-gigagen-cobra-biologics\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-31T12:10:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/31173734\/covid-19.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"COVID-19 Vaccine Update; Abbott's POC test; Cobra Bio raises $ 3.3M","description":"The US FDA has approved Abbott's new point-of-care test for the novel coronavirus (COVID-19) under EUA. Abbott's new assay can deliver the results in five..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-j-and-j-abbott-gigagen-cobra-biologics","og_locale":"en_US","og_type":"article","og_title":"COVID-19 Vaccine Update; Abbott's POC test; Cobra Bio raises $ 3.3M","og_description":"The US FDA has approved Abbott's new point-of-care test for the novel coronavirus (COVID-19) under EUA. Abbott's new assay can deliver the results in five..","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-j-and-j-abbott-gigagen-cobra-biologics","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-03-31T12:10:39+00:00","article_modified_time":"2021-07-24T07:27:51+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/31173734\/covid-19.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-j-and-j-abbott-gigagen-cobra-biologics","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-j-and-j-abbott-gigagen-cobra-biologics","name":"COVID-19 Vaccine Update; Abbott's POC test; Cobra Bio raises $ 3.3M","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-j-and-j-abbott-gigagen-cobra-biologics#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-j-and-j-abbott-gigagen-cobra-biologics#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/31173734\/covid-19.jpg","datePublished":"2020-03-31T12:10:39+00:00","dateModified":"2021-07-24T07:27:51+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The US FDA has approved Abbott's new point-of-care test for the novel coronavirus (COVID-19) under EUA. Abbott's new assay can deliver the results in five..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-j-and-j-abbott-gigagen-cobra-biologics"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-j-and-j-abbott-gigagen-cobra-biologics#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/31173734\/covid-19.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/31173734\/covid-19.jpg","width":772,"height":482,"caption":"Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/31173734\/covid-19-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Abbott<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cobra Biologics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COVID-19<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ebola Vaccine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GigaGen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Johnson and Johnson<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">LabCorp<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">PerkinElmer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Quest Diagnostics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Truvian Sciences<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Abbott<\/span>","<span class=\"advgb-post-tax-term\">Cobra Biologics<\/span>","<span class=\"advgb-post-tax-term\">COVID-19<\/span>","<span class=\"advgb-post-tax-term\">Ebola Vaccine<\/span>","<span class=\"advgb-post-tax-term\">GigaGen<\/span>","<span class=\"advgb-post-tax-term\">Johnson and Johnson<\/span>","<span class=\"advgb-post-tax-term\">LabCorp<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">PerkinElmer<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Quest Diagnostics<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">Truvian Sciences<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Mar 31, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Mar 31, 2020 5:40 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=8790"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8790\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/8798"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=8790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=8790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=8790"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=8790"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=8790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}